key: cord-0702537-ig2c8wpt
authors: Sah, Pratha; Moghadas, Seyed M; Vilches, Thomas N; Shoukat, Affan; Singer, Burton H; Hotez, Peter J; Schneider, Eric C; Galvani, Alison P
title: Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas
date: 2021-10-07
journal: Lancet Infect Dis
DOI: 10.1016/s1473-3099(21)00620-4
sha: ae27d084c21b665009db44eb33cf87d612784ba6
doc_id: 702537
cord_uid: ig2c8wpt

nan

. Mixing patterns and the daily number of contacts derived from empirical observations. 3, 4 Daily numbers of contacts were sampled from negative binomial distributions for different scenarios. 

The per-contact transmission probability of the original Wuhan-I strain of SARS-CoV-2 was calibrated by fitting the model to case incidence data per 100,000 population in Florida and Texas from October 1, 2020, to July 31, 2021. 5 We chose October 1 as the starting point for our calibration and simulations because it was a time of a relatively low incidence preceding the fall/winter wave in these two states. The calibration resulted in the per-contact transmission probabilities of 0.106 and 0.067 during the pre-symptomatic stage in Florida and Texas, respectively. In Florida, Alpha and Gamma were introduced on December 15, 2020, Iota on January 15, 2021, and Delta on April 4, 2021. 6 In Texas, Alpha was introduced on July 21, 2020, Gamma on January 17, 2021, and Delta on March 29, 2021. 7 The transmissibilities of Alpha, Gamma, Iota, were assumed to be 50%, 60%, 35% higher than the original strain, and the transmissibility of Delta was assumed to be 30% higher than Alpha. [8] [9] [10] [11] [12] [13] Disease dynamics The infectivity of asymptomatic, mild symptomatic, and severe symptomatic states was set to 26%, 44%, and 89% relative to the pre-symptomatic stage. [14] [15] [16] The incubation period was sampled from a log-normal distribution with a mean of 5.2 days. 17 An age-dependent proportion of infected individuals progressed to a pre-symptomatic stage 18 with a mean duration of 2.3 days, sampled from a Gamma distribution. 15, 19 Pre-symptomatic cases developed symptomatic disease with an average infectious period of 3.2 days, which was also sampled from a Gamma distribution. 20, 21 Infected individuals who remained asymptomatic had an average infectious period of 5 days sampled from a Gamma distribution. 20, 21 Based on the reduced neutralizing activity of convalescent sera against Gamma and Delta, [22] [23] [24] [25] we assumed that these variants evade naturally acquired immunity by an average of 21% (95% CI: 11-36%). 26, 27 This evasion rate was implemented as a reduction of immune protection for individuals recovered from the original strain or the Alpha variant, corresponding to per-contact transmission probability of 0.0223 and 0.014 in Florida and Texas. We further assumed that recovery from infection due to the Gamma or Delta variant provides protection against all variants in the model, preventing reinfection for at least one year.

We assumed that asymptomatic and mild symptomatic cases recover from infection without hospitalization. Severely ill cases were hospitalized within 2-5 days of symptom onset 28, 29 and were therefore removed from the transmission chain. All symptomatic cases who were not hospitalized were assumed to self-isolate within 24 hours of symptom onset, reducing their number of daily contacts by an average of 74% (Table S1 ). Intensive care unit (ICU) and non-ICU hospitalization rates were parameterized (Table S2 ) by clinical and epidemiological data stratified by age and comorbidities. [30] [31] [32] Infection with Alpha and Delta variants was associated with 30% higher risk of death, 9, 10 and infections with the Gamma variant were assigned the case fatality of the original strain. The risk of hospitalization with the Delta variant was assumed to be 2.26 times higher than that due to infection with Alpha. 33 

We implemented a two-dose vaccination campaign with a sequential prioritization of (i) healthcare workers (5% of the total population) 36 , adults with comorbidities, and those aged 65 and older; and (ii) other individuals aged 16-64 37, 38 . Daily vaccination rates were implemented based on the number of vaccine doses administered in different age groups 39, 40 . The minimum age-eligibility for vaccination was 16 years before May 13, 2021 after which children aged 12 to 15 years became eligible for vaccination.

The time interval between first and second doses of Pfizer-BioNTech and Moderna vaccines were specified to be 21 and 28 days, respectively. 41, 42 The model was parameterized with published estimates of vaccine efficacy following each dose of Pfizer-BioNTech and Moderna vaccines against infection, symptomatic disease, and severe disease [43] [44] [45] [46] (Table S3) . These efficacies were implemented in the model as a reduction of transmission probability (for efficacy against infection), reduction in the probability of developing symptomatic disease, and reduction of severe illness if symptomatic disease occurred.

For the counterfactual scenario of achieving 74% vaccination coverage of adults by July 31, 2021 in Florida and Texas, we increased the daily vaccine doses in the model by 32% and 35%. The additional vaccines were distributed to individuals aged 18 and older in the same priority as described above. * Vaccine efficacy against the Gamma variant was assumed to be the same as those reported for Beta.

We simulated the model with a population of 100,000 individuals for each state from October 1, 2020 to July 31, 2021. This population is a scalable size in agent-based modelling and is considered sufficiently large to capture the heterogeneity. At the start of simulations, we considered pre-existing immunity levels of 5.7% and 5.8% in Florida and Texas, respectively. 55 Vaccination was initiated on December 12, 2020, and rolled out as a two-dose strategy. On April 2, the guidelines by the US Centers for Disease Control and Prevention indicated a minimal risk for fully vaccinated individuals to return to pre-pandemic normal activities 56 . We therefore allowed vaccinated individuals to return to their normal contact pattern behaviour 14 days after the second dose of vaccine from April 3, 2021. The simulations were performed using a daily time-step and the model timelines correspond to the period of October 1, 2020 to October 31, 2021. The results were averaged over 500 independent Monte-Carlo realizations, which were sufficient for stabilization. The model was implemented in Julia, and simulation codes are available at: https://github.com/thomasvilches/multiple_strains/tree/TXnFL

We further projected the epidemiological impact of a 50% increase in the daily vaccination rate compared to the status quo in the two states, starting from September 1, 2021 (Orange curves in Figure 1 and Figures A1-A2 For both counterfactuals scenarios of 74% vaccination coverage (by July 31, 2021) and 50% increase in the daily vaccination rate (starting from September 1, 2021), we performed Kruskal-Wallis (one-way ANOVA) tests to determine the significance in reduction of cases, hospitalizations and deaths at a 5% significance level. For the first counterfactual, the null hypothesis was rejected (p-value<0.0001) for all measures in Florida and Texas, and thus the distributions of the total number of infections, hospitalizations, and deaths were significantly different from the observed data. For the second counterfactual scenario, the Kruskal-Wallis test did not reject the null hypothesis that all simulated data samples come from the same distributions (p-value>0.25). 

Few studies have also attempted to project the epidemiological impact of non-pharmacologic measures and vaccination in Florida and Texas. [57] [58] [59] . For example, a study calibrated to outbreak data in Florida prior to vaccine rollout, projected that a highly effective vaccine could avert more than 2 million infections and 55,000 deaths under 75% vaccine coverage. 59 This study, however, was conducted before vaccine rollout and did not account for transmission dynamics of SARS-CoV-2 variants. Other studies have projected the expected number of cases, 60 hospitalizations and ICU admissions 61 under status-quo vaccination rates. To our knowledge, the impact of a counterfactual scenario of boosted vaccination in Florida and Texas taking into account the transmission dynamics of SARS-CoV-2 variants and actual vaccine rollout data has not been investigated.

For the impact of enhanced vaccination programs, we note that our simulations are subject to some limitations. We considered vaccine distributions and the efficacy data of the Pfizer-BioNTech and Moderna vaccines. Combined, these two vaccines constitute ~96% of doses administered in the United States. A third single-dose vaccine developed by Johnson and Johnson is also authorized for emergency use in the United States, which has a slightly lower efficacy compared to the Pfizer-BioNTech and Moderna vaccines. 62, 63 Considering the lower efficacy of Johnson and Johnson in preventing infection, symptomatic and severe disease, our results might be subject to an overestimate of vaccination impact in reducing COVID-19 burden.

COVID-19 deaths and hospitalizations averted by rapid vaccination rollout in the United States

Social contacts and mixing patterns relevant to the spread of infectious diseases

Quantifying the impact of physical distance measures on the transmission of COVID-19 in the UK

The New York Times. Coronavirus (Covid-19) Data in the United States. Github

Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil

A Novel and Expanding SARS-CoV-2 Variant, B.1.526, Identified in New York

Increased household transmission of COVID-19 cases associated with SARS-CoV-2 Variant of Concern B.1.617.2: a national case-control study

Quantifying SARS-CoV-2 transmission suggests epidemic control with digital contact tracing

The implications of silent transmission for the control of COVID-19 outbreaks

Infectivity of asymptomatic versus symptomatic COVID-19

Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia

Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis

Temporal dynamics in viral shedding and transmissibility of COVID-19

Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2)

Spread and dynamics of the COVID-19 epidemic in Italy: Effects of emergency containment measures

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

Coronavirus variants are spreading in India -what scientists know so far

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa. Estimates of severity and transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation

Projecting demand for critical care beds during COVID-19 outbreaks in Canada

Projecting hospital utilization during the COVID-19 outbreaks in the United States

Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed Coronavirus disease 2019 -COVID-NET, 14 states

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 -United States

Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Clinical Characteristics of Coronavirus Disease 2019 in China

High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2

Number of hospitals and hospital employment in each state in 2019

Discussion draft of the preliminary framework for equitable allocation of COVID-19 vaccine

How CDC is making COVID-19 vaccine recommendations

COVID-19 vaccination demographics in the United States

COVID-19 vaccination Trends in the United States, National and jurisdictional

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Evaluation of COVID-19 vaccination strategies with a delayed second dose

Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19 variants

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system

National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Vaccines and related biological products advisory committee December 10, 2020 meeting briefing document. U.S. Food and Drug Administration

Interpreting vaccine efficacy trial results for infection and transmission

Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization

COVID-19 vaccine candidates

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. bioRxiv

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. bioRxiv

Estimated SARS-CoV-2 Seroprevalence in the US as of

Interim public health recommendations for fully vaccinated people

COVID-19 Models -Projections for delta wave COVID-19 surge in Florida

Projected COVID-19 epidemic in the United States in the context of the effectiveness of a potential vaccine and implications for social distancing and face mask use

COVID-19 Models -Projections for delta wave COVID-19 surge in Florida

Comparison of Neutralizing Antibody Titers Elicited by mRNA and Adenoviral Vector Vaccine against SARS-CoV-2 Variants

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19